The US is the bigger Bone Cancer Diagnostic market: $462 Mn against $88 Mn in 2023, about 5.2 times as large.
China grows faster: 8.9% a year, against 5.4%. The gap still grows from $374 Mn to $574 Mn by 2033.
Clinical research: 667 active trials in the US, 158 in China.
| Measure |  US |  China |
|---|---|---|
| Market size, 2023 | $462 Mn | $88 Mn |
| Market size, 2033 projected | $782 Mn | $207 Mn |
| Growth a year (CAGR) | 5.4% | 8.9% |
| Money added, 2023–2033 | $320 Mn | $119 Mn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $1.35 | $0.06 |
| Active clinical trials | 667 | 158 |
| Full report | US report | China report |
Year by year, 2023 to 2033
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Bone Cancer Diagnostic, US or China?
The US is the bigger Bone Cancer Diagnostic market: $462 Mn against $88 Mn in 2023, about 5.2 times as large.
Which grows faster in Bone Cancer Diagnostic, US or China?
China grows faster: 8.9% a year, against 5.4%. The gap still grows from $374 Mn to $574 Mn by 2033.
More Bone Cancer Diagnostic comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.